
Innoviva, Inc. (NASDAQ:INVA – Free Report) – Research analysts at HC Wainwright cut their Q4 2026 earnings estimates for Innoviva in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $0.53 per share for the quarter, down from their prior estimate of $0.54. The consensus estimate for Innoviva’s current full-year earnings is $1.52 per share. HC Wainwright also issued estimates for Innoviva’s Q3 2027 earnings at $0.57 EPS and Q4 2027 earnings at $0.63 EPS.
Innoviva (NASDAQ:INVA – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of $0.52 by ($1.55). The business had revenue of $106.12 million for the quarter, compared to analysts’ expectations of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%.
INVA has been the topic of a number of other research reports. Wall Street Zen lowered Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Cantor Fitzgerald reduced their price objective on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Zacks Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Oppenheimer lowered their target price on Innoviva from $35.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, November 5th. Finally, Weiss Ratings raised Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, November 9th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.
Read Our Latest Stock Analysis on Innoviva
Innoviva Stock Performance
Shares of INVA stock opened at $18.49 on Monday. The company has a quick ratio of 14.58, a current ratio of 15.44 and a debt-to-equity ratio of 0.23. Innoviva has a 52 week low of $18.41 and a 52 week high of $25.15. The stock has a market capitalization of $1.31 billion, a PE ratio of 5.47, a P/E/G ratio of 4.15 and a beta of 0.38. The firm has a 50 day moving average of $20.64 and a two-hundred day moving average of $21.85.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in INVA. Dimensional Fund Advisors LP raised its holdings in shares of Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after purchasing an additional 76,026 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Innoviva during the 2nd quarter worth $77,562,000. Bank of America Corp DE acquired a new position in shares of Innoviva during the second quarter worth $37,873,000. Deutsche Bank AG acquired a new position in shares of Innoviva during the second quarter worth $20,847,000. Finally, William Blair Investment Management LLC grew its stake in shares of Innoviva by 29.7% during the third quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company’s stock worth $17,665,000 after purchasing an additional 190,705 shares in the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.
Innoviva Company Profile
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Read More
- Five stocks we like better than Innoviva
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
